August 3, 2026
Perseus Proteomics Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Perseus Proteomics and Eurus Therapeutics Enter into a New Joint Research Agreement

Perseus Proteomics Co., Ltd. (“PPMX”) and Eurus Therapeutics Co., Ltd. (“Eurus”) have been conducting joint research* aimed at creating novel therapeutics by leveraging the synergistic combination of PPMX’s proprietary PPMX Antibody Library 2 and Eurus’s novel genome-editing technology. As a result, the companies confirmed results that will enable further progress in the joint research, particularly in obtaining the target antibodies and antibody genes.

PPMX and Eurus hereby announce that they have entered into a new joint research agreement, as the next step in their ongoing joint research, to profile and optimize the antibodies and antibody genes obtained through the research.

The companies will disclose updates on the progress and results of the research, as well as the achievement of milestones, as appropriate.

The impact of this agreement on PPMX’s financial results is currently expected to be immaterial.

* Notice of Joint Research Agreement with Eurus Therapeutics Inc. for the Utilization of PPMX Antibody Library
Reference URL: https://contents.xj-storage.jp/xcontents/AS82027/65e91c52/1cb2/42c4/83c6/1a1dcf47b4be/140120251117504729.pdf

Eurus Therapeutics Co., Ltd. — Company Profile

Head office	Fujisawa, Kanagawa, Japan
Representative Director	Takato Nomi
Established	February 2021
Business description	Development of novel gene therapy methods